Breast Cancer
The digital pathology software developer is raising funding that would help it to increase its head count and support its Aiosyn Mitosis Breast application.
Lumea to Incorporate Myriad Genetics Cancer Tests Into Digital Pathology Platform
Under the collaboration, the firms will make Myriad's Prolaris prostate cancer and MyRisk hereditary cancer tests available through Lumea's BxLink digital pathology platform.
FDA Approves Roche Antibody Test as CDx for Enhertu in HER2-Ultralow Breast Cancer Patients
The tissue-based test is approved to identify a new classification in HER2 expression designated as HER2-ultralow.
Aiosyn Gains CE-IVDR Mark for Breast Cancer Mitosis Counting Software
The Netherlands-based firm said that its Aiosyn Mitosis Breast software is used to aid tumor grading and provide a prognostic indicator to guide treatment decisions.
Data from Myriad Genetics offered early validation evidence for an expanded version of its commercial test, as well as a look into clinical impact via claims data.